Abstract:Introduction Liver disease is a leading cause of morbidity and mortality among persons living with HIV (PLHIV). While chronic viral hepatitis has been extensively studied in low‐ and middle‐income countries (LMICs), there is limited information about the burden of metabolic disorders on liver disease in PLHIV. Methods We conducted a cross‐sectional analysis of baseline data collected between October 2020 and July 2022 from the IeDEA‐Sentinel Research Network, a prospective cohort enrolling PLHIV ≥40 years on antiretroviral treatment (ART) for ≥6 months from eight clinics in Asia, Americas, and central, East, southern and West Africa. Clinical assessments, laboratory testing on fasting blood samples and liver stiffness measurement (LSM)/controlled attenuation parameter (CAP) by vibration‐controlled transient elastography were performed. Multivariable logistic regression models assessed factors associated with liver fibrosis (LSM ≥7.1 kPa) and steatosis (CAP ≥248 dB/m). Population attributable fraction (PAF) of each variable associated with significant liver fibrosis was estimated using Levin's formula. Results Overall, 2120 PLHIV (56% female, median age 50 [interquartile range: 45−56] years) were included. The prevalence of obesity was 19%, 12% had type 2 diabetes mellitus (T2DM), 29% had hypertension and 53% had dyslipidaemia. The overall prevalence of liver fibrosis and steatosis was 7.6% (95% confidence interval [CI] 6.1−8.4) and 28.4% (95% CI 26.5−30.7), respectively, with regional variability. Male sex at birth (odds ratio [OR] 1.62, CI 1.10−2.40), overweight/obesity (OR = 2.50, 95% CI 1.69−3.75), T2DM (OR 2.26, 95% CI 1.46−3.47) and prolonged exposure to didanosine (OR 3.13, 95% CI 1.46−6.49) were associated with liver fibrosis. Overweight/obesity and T2DM accounted for 42% and 11% of the PAF for liver fibrosis, while HBsAg and anti‐HCV accounted for 3% and 1%, respectively. Factors associated with steatosis included overweight/obesity (OR 4.25, 95% CI 3.29−5.51), T2DM (OR 2.06, 95% CI 1.47−2.88), prolonged exposure to stavudine (OR 1.69, 95% CI 1.27−2.26) and dyslipidaemia (OR 1.68, 95% CI 1.31−2.16). Conclusions Metabolic disorders were significant risk factors for liver disease among PLHIV in LMICs. Early recognition of metabolic disorders risk factors might be helpful to guide clinical and lifestyle interventions. Further prospective studies are needed to determine the causative natures of these findings.

Metabolic causes of liver disease among adults living with HIV from low‐ and middle‐income countries: a cross‐sectional study

Association of cardiovascular disease risk with liver steatosis and fibrosis in people living with hiv in low- and middle-income countries

Nonviral Liver Disease Burden in People Living With HIV and Elevated Transaminases: A Cross-Sectional Study

Burden of liver steatosis and liver fibrosis in a large cohort of people living with HIV

Plasma proteomic signatures of liver steatosis and fibrosis in people living with HIV: a cross-sectional study

Severe Dyslipidemia and Immune Activation in HIV Patients with Dysglycemia

Prevalence and risk factors of metabolic dysfunction‐associated steatotic liver disease in south Central Uganda: A cross‐sectional survey

The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV

Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease among People Living with HIV in China

Burden of significant liver damage in people living with HIV after microelimination of the hepatitis C virus.

Metabolic Dysfunction-Associated Steatotic Liver Disease in People Living with HIV—Limitations on Antiretroviral Therapy Selection

Factors Associated With Liver Steatosis in People With Human Immunodeficiency Virus on Contemporary Antiretroviral Therapy

Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States

Fatty Liver Disease: Enter the Metabolic Era

"Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV"

Predictors of liver disease progression in people living with HIV-HBV co-infection on antiretroviral therapy

Impact of Human Immunodeficiency Virus Infection on Liver and Cardiovascular Outcomes in Veterans with Metabolic Dysfunction Associated Steatotic Liver Disease

Microbial Translocation is Associated with Advanced Liver Fibrosis among People with HIV

Metabolic dysfunction-associated steatohepatitis exhibits sex differences in people with HIV

MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV

MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls